Elutia Inc (ELUT) Stock Price, Quote & News

Company Profile

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for ca...

Industry: Medical Devices

Sector: Healthcare

Phone: 240 247 1170

Fax: 510 307 9896

Website: elutia.com

Address:

20 Firstfield Road, Gaithersburg, United States

Rasputinn May. 29 at 3:30 PM

$ELUT The stock is more or less dead at this point. The market has lost faith on the management after the low balling of ELUPRO. It is highly unlikely that the stock will recover beyond 1.5 USD this year. Next year they will run out of cash, so there is dilution risk. The new product market size appears to be very niche and is dependent on reimbursements. Unless, a big pharma intervenes and takes it over there will be no infusion of funds from private equities or institutional investors.

2 · Reply

StocktwitsEarnings May. 14 at 8:15 PM

$ELUT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.17 down -70.00% YoY • Reported revenue of $3.11M down -48.36% YoY • Anticipated clearance for Elutia's NXT-41 is on track for Q4 2026, with NXT-41x expected in H1 2027. The company expects its new manufacturing platform to support a gross margin exceeding 80% at scale.

0 · Reply

newsfile_corp May. 14 at 8:02 PM

https://nfne.ws/297484 $ELUT #InvitationalXVI #ldmicro #Publishing #NASDAQ #Investing

0 · Reply

BillionerOfKing Apr. 30 at 1:13 AM

$ELUT Current Stock Price: $1.01

0 · Reply

SuperGreenToday Apr. 7 at 6:47 PM

$ELUT

0 · Reply

Invest2live Apr. 4 at 1:22 AM

$ELUT 59% already; congrats 🌿🎈🌿 Checkout $GAU and $RXRX

0 · Reply

OfficialStocktwitsUser Apr. 1 at 6:17 PM

$ELUT RSI: 46.07, MACD: 0.0047 Vol: 0.03, MA20: 1.09, MA50: 1.06 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Sidoti Mar. 20 at 10:09 PM

Elutia Inc. ($ELUT) Management Team presented at the Sidoti Small-Cap Virtual Conference this week. Watch the replay here: https://sidoti.zoom.us/webinar/register/WN_bckjL702SRKzQIv2dFlBOg

0 · Reply

Sidoti Mar. 19 at 6:50 PM

Presenting now at the virtual #SidotiConference $ELUT $STKS https://www.meetmax.com/sched/event_132523/conference_presentations.html

0 · Reply

StocktwitsEarnings Mar. 11 at 9:54 PM

$ELUT Q4 '25 Earnings Results & Recap Elutia anticipates FDA clearance for its base biologic matrix NXT-41 in the second half of 2026, with full NXT-41x drug-eluting biologic clearance expected in the first half of 2027.

0 · Reply

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026, 2:30 PM EDT - 11 days ago

Elutia Transcript: 16th Annual LD Micro Invitational Conference

May 14, 2026, 5:00 PM EDT - 15 days ago

Elutia Earnings Call Transcript: Q1 2026

May 14, 2026, 5:00 PM EDT - 15 days ago

Elutia Earnings release: Q1 2026

May 14, 2026, 5:00 PM EDT - 15 days ago

Elutia Slides: Q1 2026

May 14, 2026, 5:00 PM EDT - 15 days ago

Elutia Quarterly report: Q1 2026

May 14, 2026, 4:05 PM EDT - 15 days ago

Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

May 14, 2026, 4:01 PM EDT - 15 days ago

Elutia to Present at the 16th Annual LD Micro Invitational on May 18th

May 14, 2026, 4:01 PM EDT - 15 days ago

Elutia to Present at the 16th Annual LD Micro Invitational May 18th

Apr 30, 2026, 4:05 PM EDT - 4 weeks ago

Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Apr 22, 2026, 8:00 AM EDT - 5 weeks ago

Elutia Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 5 weeks ago

Elutia Proxy statement: Proxy filing

Mar 19, 2026, 2:30 PM EDT - 2 months ago

Elutia Transcript: Sidoti March Small-Cap Virtual Conference

Mar 17, 2026, 8:00 AM EDT - 2 months ago

Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19

2026-03-13T12:11:48.000Z - 2 months ago

Elutia announces grants of inducement awards

Mar 11, 2026, 5:00 PM EDT - 2 months ago

Elutia Earnings Call Transcript: Q4 2025

Mar 11, 2026, 5:00 PM EDT - 2 months ago

Elutia Annual report: Q4 2025

Mar 11, 2026, 5:00 PM EDT - 2 months ago

Elutia Earnings release: Q4 2025

Mar 11, 2026, 5:00 PM EDT - 2 months ago

Elutia Slides: Q4 2025

Mar 11, 2026, 4:05 PM EDT - 2 months ago

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

2026-03-04T13:14:05.000Z - 3 months ago

Elutia regains compliance with Nasdaq listing requirements

Mar 4, 2026, 8:00 AM EST - 3 months ago

Elutia Regains Compliance with Nasdaq Listing Requirements

2026-03-02T13:42:05.000Z - 3 months ago

Elutia appoints Ligotti as Chief Commercial Officer

Mar 2, 2026, 8:00 AM EST - 3 months ago

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

Feb 25, 2026, 4:05 PM EST - 3 months ago

Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

Feb 18, 2026, 8:00 AM EST - 3 months ago

Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

2026-01-12T13:16:18.000Z - 4 months ago

Elutia reports preliminary Q4 revenue $3.3M

Jan 12, 2026, 8:00 AM EST - 4 months ago

Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones

Jan 9, 2026, 8:00 AM EST - 5 months ago

Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery

2025-11-25T15:10:18.000Z - 6 months ago

Elutia management to meet with Lake Street

2025-11-06T22:25:42.000Z - 7 months ago

Elutia reports Q3 EPS (19c) vs. (33c) last year

Nov 6, 2025, 5:00 PM EST - 7 months ago

Elutia Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Elutia Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Elutia Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Elutia Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 7 months ago

Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development

Oct 23, 2025, 4:05 PM EDT - 7 months ago

Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 21, 2025, 4:00 PM EDT - 7 months ago

Elutia Transcript: LD Micro Main Event XIX Investor Conference

Oct 21, 2025, 4:00 PM EDT - 7 months ago

Elutia Slides: LD Micro Main Event XIX Investor Conference

Oct 14, 2025, 4:05 PM EDT - 8 months ago

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21

2025-10-10T12:06:30.000Z - 8 months ago

Elutia appoints Guido Neels to board of directors

Oct 10, 2025, 8:00 AM EDT - 8 months ago

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors

2025-10-01T12:45:35.000Z - 8 months ago

Elutia closes sale of its BioEnvelope business to Boston Scientific for $88M

BSX

Oct 1, 2025, 8:41 AM EDT - 8 months ago

Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million

2025-09-16T12:20:45.000Z - 9 months ago

Elutia announces publication clinical, preclinical data on biologic envelope

Sep 16, 2025, 8:00 AM EDT - 9 months ago

Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation

2025-09-10T12:35:33.000Z - 9 months ago

Elutia price target lowered to $6 from $8 at Lake Street

BSX

2025-09-09T12:50:11.000Z - 9 months ago

Elutia Inc trading resumes

2025-09-09T12:37:59.000Z - 9 months ago

Elutia announces sale of bioenvelopes business to Boston Scientific for $88M

BSX

Sep 9, 2025, 8:30 AM EDT - 9 months ago

Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million

2025-09-09T12:25:09.000Z - 9 months ago

Elutia Inc trading halted, news pending

Sep 4, 2025, 9:45 AM EDT - 9 months ago

Elutia Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 9 months ago

Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange

Aug 27, 2025, 8:00 AM EDT - 9 months ago

Elutia to Participate in Upcoming Investor Conferences

2025-08-18T13:55:53.000Z - 10 months ago

Elutia price target lowered to $5 from $7 at Cantor Fitzgerald

Aug 14, 2025, 5:00 PM EDT - 10 months ago

Elutia Earnings Call Transcript: Q2 2025

Aug 14, 2025, 5:00 PM EDT - 10 months ago

Elutia Quarterly report: Q2 2025

Aug 14, 2025, 5:00 PM EDT - 10 months ago

Elutia Earnings release: Q2 2025

Aug 14, 2025, 5:00 PM EDT - 10 months ago

Elutia Slides: Q2 2025

Aug 14, 2025, 4:05 PM EDT - 10 months ago

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption

Jul 31, 2025, 4:05 PM EDT - 10 months ago

Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Jul 31, 2025, 8:00 AM EDT - 10 months ago

Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award

2025-07-01T12:15:08.000Z - 11 months ago

Elutia announces publication of new study on CIED biologic envelope

Jul 1, 2025, 8:00 AM EDT - 11 months ago

New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards

2025-05-28T12:16:13.000Z - 1 year ago

Elutia announces publication of article on measuring antibiotic release

May 28, 2025, 8:00 AM EDT - 1 year ago

Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

2025-05-09T13:25:14.000Z - 1 year ago

Elutia price target lowered to $8 from $10 at Lake Street

May 8, 2025, 5:00 PM EDT - 1 year ago

Elutia Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Elutia Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Elutia Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Elutia Slides: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

2025-05-01T21:25:29.000Z - 1 year ago

Elutia reclaims sales, distribution for cardiovascular portfolio

May 1, 2025, 4:05 PM EDT - 1 year ago

Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

May 1, 2025, 8:00 AM EDT - 1 year ago

Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

Apr 23, 2025, 4:00 PM EDT - 1 year ago

Elutia Transcript: Planet MicroCap Showcase: VEGAS 2025

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29

2025-04-21T12:12:45.000Z - 1 year ago

Elutia initiates EluPro clinical study to collect real-world outcome data

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Elutia Confirms No Material Impact from Global Tariffs

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Elutia Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Elutia Proxy statement: Proxy Filing

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

Mar 25, 2025, 4:05 PM EDT - 1 year ago

Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Elutia Registration statement: Registration Filing

Mar 6, 2025, 4:30 PM EST - 1 year ago

Elutia Earnings Call Transcript: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Elutia Annual report: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Elutia Earnings release: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Elutia Slides: Q4 2024

Mar 6, 2025, 4:05 PM EST - 1 year ago

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

Feb 20, 2025, 4:05 PM EST - 1 year ago

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

Feb 3, 2025, 6:30 AM EST - 1 year ago

Elutia Announces $15.0 Million Registered Direct Offering

Nov 14, 2024, 4:30 PM EST - 1 year ago

Elutia Earnings Call Transcript: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Elutia Quarterly report: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Elutia Earnings release: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Elutia Slides: Q3 2024

Oct 30, 2024, 5:00 PM EDT - 1 year ago

Elutia Transcript: 17th Annual LD Micro Main Event Conference

Oct 23, 2024, 4:05 PM EDT - 1 year ago

Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company's Antibiotic-Eluting BioEnvelope for Implantable Devices

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Elutia Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 6, 2024, 4:23 PM EDT - 1 year ago

Elutia Celebrates First Year

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD EUDA GDTC GOSS GOVX IMRN

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Elutia Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Elutia Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Elutia Earnings release: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Elutia Slides: Q2 2024

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

Jul 11, 2024, 4:05 PM EDT - 2 years ago

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

Jun 17, 2024, 8:01 AM EDT - 2 years ago

Elutia Announces $13.26 Million Registered Direct Offering

Jun 17, 2024, 8:00 AM EDT - 2 years ago

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

May 9, 2024, 4:30 PM EDT - 2 years ago

Elutia Earnings Call Transcript: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Elutia Quarterly report: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Elutia Earnings release: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Elutia Slides: Q1 2024

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1

Rasputinn May. 29 at 3:30 PM

2 · Reply

StocktwitsEarnings May. 14 at 8:15 PM

0 · Reply

newsfile_corp May. 14 at 8:02 PM

https://nfne.ws/297484 $ELUT #InvitationalXVI #ldmicro #Publishing #NASDAQ #Investing

0 · Reply

BillionerOfKing Apr. 30 at 1:13 AM

$ELUT Current Stock Price: $1.01

0 · Reply

SuperGreenToday Apr. 7 at 6:47 PM

$ELUT

0 · Reply

Invest2live Apr. 4 at 1:22 AM

$ELUT 59% already; congrats 🌿🎈🌿 Checkout $GAU and $RXRX

0 · Reply

OfficialStocktwitsUser Apr. 1 at 6:17 PM

0 · Reply

Sidoti Mar. 20 at 10:09 PM

Elutia Inc. ($ELUT) Management Team presented at the Sidoti Small-Cap Virtual Conference this week. Watch the replay here: https://sidoti.zoom.us/webinar/register/WN_bckjL702SRKzQIv2dFlBOg

0 · Reply

Sidoti Mar. 19 at 6:50 PM

Presenting now at the virtual #SidotiConference $ELUT $STKS https://www.meetmax.com/sched/event_132523/conference_presentations.html

0 · Reply

StocktwitsEarnings Mar. 11 at 9:54 PM

0 · Reply

EyeYamStewPeed Mar. 11 at 8:34 PM

$ELUT what a joke; pump n dump

0 · Reply

palo34 Mar. 11 at 8:32 PM

$ELUT my best performing stock, but got small and added few dollars here and there. I did not anticipate consistant growth.

0 · Reply

Invest2live Feb. 24 at 7:00 PM

$ELUT 59% already; congrats 🎈 🌿; anything below 1.30 is cheap for $HUMA.

0 · Reply

Geddymd72 Feb. 21 at 1:11 AM

$ELUT Got in small at 0.75 last month. Biotech companies are risky. Get them while they are cheap and dont lose your shirt.

0 · Reply

algo888 Feb. 19 at 4:58 PM

$GERN $ERNA $IMUX $ELUT Go ALL in now on IMUX Inching up closer and closer to the high of day breakout..

0 · Reply

lucidi Feb. 18 at 5:00 PM

$ELUT already up over 100%. looks like it is just getting started. glta

0 · Reply

S2K_TP Feb. 15 at 5:26 AM

$ELUT on watch 🦉

1 · Reply

Market Cap	47.92M
Revenue (ttm)	12.29M
Net Income (ttm)	53.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	434.34%
Debt to Equity Ratio	0.00

Volume	75,000
Avg Vol	106,360
Day's Range	N/A - N/A
Shares Out	42.79M
Stochastic %K	54%
Beta	0.75
Analysts	Strong Sell
Price Target	$5.00